Alzheimer’s Drug Buntanetap to Get New Research Updates
The investigational treatment is set for upcoming clinical presentations before a major trial data readout in early 2027.
Updated on Oct. 28, 2026 in Alzheimer’s
Live Poll
Do you feel optimistic that new drug research will lead to effective Alzheimer's treatments?
Annovis Bio Inc. is preparing three upcoming research presentations on its investigational Alzheimer’s drug, buntanetap, at the 19th Clinical Trials on Alzheimer’s Disease conference. The findings will provide updates for adults with early Alzheimer’s disease ahead of a pivotal Phase 3 clinical trial readout expected in early 2027.
Why it matters
These presentations serve as a progress update for the potential development of a new treatment option designed to inhibit the production of neurotoxic proteins in the brain. The findings offer a preview for families tracking the drug's advancement toward a potential New Drug Application with the FDA.
Annovis Bio Inc. will present three research updates on buntanetap, an investigational oral therapy currently being studied in patients with early-stage Alzheimer's disease. Whether this mechanism of inhibiting neurotoxic protein translation effectively improves patient outcomes remains under investigation.
The players
Annovis Bio Inc.
A pharmaceutical company headquartered in Malvern, Pennsylvania, that focuses on developing treatments for neurodegenerative conditions like Alzheimer's and Parkinson's diseases.
The details
Buntanetap functions as an oral therapy designed to inhibit the translation of specific proteins that form toxic clusters in the brains of individuals with Alzheimer's disease. By interfering with the production of these neurotoxic proteins, the drug aims to reduce the underlying molecular damage associated with disease progression. These upcoming presentations will detail the drug's mechanism of action alongside current trial design data.
Timeline
The 19th Clinical Trials on Alzheimer's Disease conference takes place from November 16-19, 2026.
Poster sessions regarding trial design and AI research are scheduled for November 16-17, 2026.
The oral presentation on the drug's mechanism of action is set for November 19, 2026, at 3:52 p.m. ET.
The company expects a Phase 3 clinical trial data readout in early 2027.
Health Landscape
This development tracks within the broader effort to find new pharmaceutical interventions for Alzheimer's disease, a field currently characterized by a search for drugs that can modify the underlying disease process. It follows the pattern of companies sharing data at this conference before pivotal readouts.
These presentations represent preliminary research updates and do not change current treatment or management strategies for Alzheimer's disease. Adults interested in the potential availability of new therapies should discuss ongoing clinical trials with their neurologist or primary care physician.
The takeaway
Investigational drugs like buntanetap are currently working through clinical trials aimed at targeting the production of proteins that drive Alzheimer’s disease. Patients and caregivers should remain focused on current, evidence-based management and consult their doctor about legitimate clinical trial opportunities.
What happens next
Annovis Bio Inc. is scheduled to release results from its Phase 3 clinical trial for buntanetap in early 2027.
Further reading
For more information on the latest research and standard of care, see our guide to Alzheimer’s.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you feel optimistic that new drug research will lead to effective Alzheimer's treatments?
